Literature DB >> 21779940

Potential errors in the volume of distribution estimation of therapeutic proteins composed of differently cleared components.

Wolfgang F Richter1, Hans Peter Grimm, Frank-Peter Theil.   

Abstract

The volume of distribution at steady state (Vss) of therapeutic proteins is usually assessed by non-compartmental or compartmental pharmacokinetic (PK) analysis wherein errors may arise due to the elimination of therapeutic proteins from peripheral tissues that are not in rapid equilibrium with the sampling compartment (usually blood). Here we explored another potential source of error in the estimation of Vss that is linked to the heterogeneity of therapeutic proteins which may consist of components (e.g. glycosylation variants) with different elimination rates. PK simulations were performed with such hypothetical binary protein mixtures where elimination was assumed to be exclusively from the central compartment. The simulations demonstrated that binary mixtures containing a rapid-elimination component can give rise to pronounced bi-phasic concentration-time profiles. Apparent Vss observed with both non-compartmental and 2-compartmental PK analysis, increased with increasing fraction as well as with increasing elimination rate k ( 10 ) of the rapid-elimination component. Simulation results were complemented by PK analysis of an in vivo study in cynomolgus monkeys with different lots of lenercept, a tumor necrosis factor receptor-immunoglobulin G1 fusion protein, with different heterogeneities. The comparative Vss data for the three lenercept lots with different amounts of rapidly cleared components were consistent with the outcome of our simulations. Both lots with a higher fraction of rapidly cleared components had a statistically significant higher Vss as compared to the reference lot. Overall our study demonstrates that Vss of a therapeutic protein may be overestimated in proteins with differently eliminated components.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21779940     DOI: 10.1007/s10928-011-9209-1

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  16 in total

1.  Distribution and elimination of 131 I- and 14C-labelled plasma proteins in the rabbit.

Authors:  S COHEN; R C HOLLOWAY; C MATTHEWS; A S MCFARLANE
Journal:  Biochem J       Date:  1956-01       Impact factor: 3.857

Review 2.  Pharmacokinetic aspects of biotechnology products.

Authors:  Lisa Tang; Adam M Persky; Günther Hochhaus; Bernd Meibohm
Journal:  J Pharm Sci       Date:  2004-09       Impact factor: 3.534

Review 3.  Antibody pharmacokinetics and pharmacodynamics.

Authors:  Evelyn D Lobo; Ryan J Hansen; Joseph P Balthasar
Journal:  J Pharm Sci       Date:  2004-11       Impact factor: 3.534

4.  Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice.

Authors:  Thomas A Millward; Markus Heitzmann; Kurt Bill; Ulrich Längle; Peter Schumacher; Kurt Forrer
Journal:  Biologicals       Date:  2007-09-24       Impact factor: 1.856

Review 5.  On the volume of distribution at steady state and its relationship with two-compartmental models.

Authors:  James W T Yates; Philip A Arundel
Journal:  J Pharm Sci       Date:  2008-01       Impact factor: 3.534

6.  Monoclonal antibody pharmacokinetics and pharmacodynamics.

Authors:  W Wang; E Q Wang; J P Balthasar
Journal:  Clin Pharmacol Ther       Date:  2008-09-10       Impact factor: 6.875

7.  Potential errors in the volume of distribution estimation of therapeutic proteins composed of differently cleared components.

Authors:  Wolfgang F Richter; Hans Peter Grimm; Frank-Peter Theil
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-07-21       Impact factor: 2.745

8.  Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys.

Authors:  Andrew J S Jones; Damon I Papac; Edward H Chin; Rodney Keck; Sharon A Baughman; Yvonne S Lin; Johannes Kneer; John E Battersby
Journal:  Glycobiology       Date:  2007-03-01       Impact factor: 4.313

9.  Animal pharmacokinetics of the tumor necrosis factor receptor-immunoglobulin fusion protein lenercept and their extrapolation to humans.

Authors:  W F Richter; H Gallati; C D Schiller
Journal:  Drug Metab Dispos       Date:  1999-01       Impact factor: 3.922

10.  Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N-acetylglucosamine content.

Authors:  Rodney Keck; Namita Nayak; Laura Lerner; Shanta Raju; Stacey Ma; Thomas Schreitmueller; Stephen Chamow; Kathy Moorhouse; Claire Kotts; Andrew Jones
Journal:  Biologicals       Date:  2007-08-28       Impact factor: 1.856

View more
  3 in total

1.  Potential errors in the volume of distribution estimation of therapeutic proteins composed of differently cleared components.

Authors:  Wolfgang F Richter; Hans Peter Grimm; Frank-Peter Theil
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-07-21       Impact factor: 2.745

Review 2.  Pharmacokinetics of recombinant bifunctional fusion proteins.

Authors:  Xiaoying Chen; Jennica L Zaro; Wei-Chiang Shen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-03-20       Impact factor: 4.481

3.  Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model.

Authors:  Yanguang Cao; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-08-22       Impact factor: 2.745

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.